Research Article

Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9

Table 3

Toxicities of compounds.

NumberZINC IDRat NTPaMouse NTPaAMESbDTPc
MaleFemaleMaleFemale

1ZINC0000622382220.9690.0000.0000.0000.9891.000
2ZINC0000855448390.9640.0000.0800.0000.9991.000
3ZINC0000956205240.9991.0000.0001.0000.0001.000
4ZINC0000040990690.0000.0000.0000.0000.0020.864
5ZINC0000046548450.0001.0001.0000.0001.0001.000
6ZINC0000855411630.9981.0001.0000.1860.0001.000
7ZINC0000085520690.9970.0000.0000.0151.0001.000
8ZINC0000135135400.8400.0200.0000.1390.0001.000
9ZINC0000042282931.0000.0000.0000.1650.0001.000
10ZINC0000092124281.0000.0000.0001.0000.3561.000
11ZINC0000149521160.0000.0000.0000.0010.0000.928
12ZINC0000147127930.6321.0000.0000.6400.0001.000
13ZINC0000116166361.0001.0001.0000.0001.0001.000
14ZINC0000082200360.0001.0001.0000.0000.0640.000
15ZINC0000040966530.0001.0001.0000.0001.0001.000
16ZINC0000124943170.0000.0000.0000.2220.0001.000
17ZINC0000149516580.0001.0000.0001.0000.0001.000
18ZINC0000858268350.9981.0001.0000.1860.0001.000
19ZINC0000428054820.9981.0001.0000.1860.0001.000
20ZINC0000040977740.0530.9870.9160.0000.0021.000
216U3X1.0000.1390.0120.0021.0001.000

a0 (noncarcinogen) and 1 (carcinogen); b0 (nonmutagen) and 1 (mutagen); c0 (nontoxic) and 1 (toxic).